Wednesday, 26 October 2016
|NZX : PEB|
26 Oct 16 16:14
Pacific Edge is a New Zealand based biomedical company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer.
Two products have recently completed successful clinical trials, bladder cancer detection and colorectal cancer prognosis (CRC). The bladder cancer technology Cxbladder® has been released to the market in Australia and New Zealand. CRC is being readied for commercial release. Pipeline products still in development include gastric and endometrial cancers and melanoma.
Cxbladder® is a non-invasive, accurate test that enables the early detection of bladder cancer from a small volume of urine providing general practitioners and urologists with a quick, cost effective and accurate measure of the presence of the cancer and provides urologists with the opportunity to reduce their reliance on the need for invasive tests such as cystoscopy.
The Company is commercialising its products from its new diagnostic laboratory in New Zealand and plans further commercialisation in the US and Europe as a centralised diagnostic service through its own facilities or as a turn-key solution, licensed to selected partners. Pacific Edge has plans for further studies in key markets to engage leading medical and urological opinion leaders who will be vital to success in new markets.
|Issuer:||Pacific Edge Limited|
|Solicitor:||Anderson Lloyd Caudwell Dunedin|
|Registry:||LINK MARKET SERVICES LIMITED|
|Auditor:||Pricewaterhouse Coopers Dunedin|
|Settlement:||NZCDC Settlement System|
|52 wk High:||0.6700|
|52 wk Low:||0.3500|
Pacific Edge Limited
87 St David Street
13:56 | 24/10/16
Hot Stock News
Pacific Edge Limited (PEB.NZ) has been a stock getting a bit more investor attention of late. Here we will take at some of the stock technicals in order to get a grasp of the trends. more»
Oct 19 Two doses of a vaccine that protects against cervical and several other types of cancer are enough for 11-to 12-year-olds, rather than the previous three-shot regimen, the U.S. more»
18:37 | 28/9/16
MSCI's broadest index of Asia-Pacific shares outside Japan was down 0.2 percent, erasing earlier modest gains. South Korea's Kospi fell 0.5 percent and Shanghai lost 0.3 percent. more»
Sagging oil, weighed down by waning hopes that a meeting of producers would reduce oversupply, also soured sentiment. MSCI's broadest index of Asia-Pacific shares outside Japan . ... "The market currently does not expect any agreement at this meeting ... more»
Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S. September 22, 2016. REUTERS/Brendan McDermid. more»
25 October 2016
CXBLADDER MONITOR ADOPTED BY WAITEMATA DISTRICT HEALTH BOARD
Cxbladder Monitor to replace cystoscopy in clinical evaluation for low risk
surveillance patient more»
20 October 2016
PACIFIC EDGE CONFIRMED AS APPROVED PROVIDER TO TRICARE NETWORK IN US
The US subsidiary of cancer diagnostics company, Pacific Edge Limited
(NZX:PEB), is now more»
20 October 2016
PACIFIC EDGE NAMED IN TIN100 TOP 10 LIST
Pacific Edge named in TIN100 Top Ten Hot Emerging Companies for 2016
The growing success of cancer diagnostics com more»
22 September 2016
PRIVATE INSURANCE COVERAGE CONFIRMED FOR CXBLADDER
Cxbladder Now Covered by nib Health Insurance
Cancer diagnostics company, Pacific Edge (NZX:PEB) has adv more»
26 August 2016
PACIFIC EDGE 2016 ANNUAL MEETING RESULTS
Pacific Edge held its Annual Meeting in Dunedin on 25 August 2016, updating
shareholders on the milestones achieved i more»
There are currently no comments on this topic.
Be the first person to Add a Comment...
You must be a registered user to post a comment: REGISTER NOW
If you are already registered, please LOGIN NOW